Shares of Laboratory Corp. of America Holdings (NYSE:LH) reached a new 52-week high during trading on Wednesday . The stock traded as high as $132.19 and last traded at $132.07, with a volume of 307,876 shares changing hands. The stock had previously closed at $130.73.

Several brokerages have recently issued reports on LH. Canaccord Genuity lifted their target price on shares of Laboratory Corp. of America Holdings from $135.00 to $140.00 and gave the company a “buy” rating in a research report on Tuesday, April 26th. Credit Suisse Group AG began coverage on shares of Laboratory Corp. of America Holdings in a research report on Tuesday, March 15th. They issued an “outperform” rating and a $133.00 target price on the stock. Robert W. Baird reiterated a “buy” rating on shares of Laboratory Corp. of America Holdings in a research report on Monday, May 16th. Morgan Stanley reiterated a “buy” rating on shares of Laboratory Corp. of America Holdings in a research report on Monday, May 2nd. Finally, Mizuho lifted their target price on shares of Laboratory Corp. of America Holdings from $119.00 to $132.00 and gave the company a “neutral” rating in a research report on Tuesday, April 26th. Six equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $135.50.

The stock has a market cap of $13.51 billion and a P/E ratio of 22.89. The company has a 50-day moving average price of $128.71 and a 200 day moving average price of $119.32.

Laboratory Corp. of America Holdings (NYSE:LH) last posted its quarterly earnings results on Monday, April 25th. The company reported $2.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.96 by $0.06. During the same period last year, the company earned $1.73 earnings per share. The company had revenue of $2.30 billion for the quarter, compared to analyst estimates of $2.19 billion. The business’s revenue for the quarter was up 29.5% compared to the same quarter last year. On average, analysts predict that Laboratory Corp. of America Holdings will post $8.79 EPS for the current fiscal year.

In other Laboratory Corp. of America Holdings news, CEO David P. King sold 196,400 shares of the firm’s stock in a transaction dated Monday, June 13th. The shares were sold at an average price of $128.00, for a total transaction of $25,139,200.00. Following the sale, the chief executive officer now directly owns 271,210 shares of the company’s stock, valued at approximately $34,714,880. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Edward T. Dodson sold 9,392 shares of the firm’s stock in a transaction dated Wednesday, April 27th. The stock was sold at an average price of $126.42, for a total transaction of $1,187,336.64. Following the sale, the insider now directly owns 2,717 shares in the company, valued at $343,483.14. The disclosure for this sale can be found here.

Several hedge funds and institutional investors recently made changes to their positions in LH. Jennison Associates LLC raised its position in shares of Laboratory Corp. of America Holdings by 57.6% in the fourth quarter. Jennison Associates LLC now owns 1,434,775 shares of the company’s stock valued at $177,396,000 after buying an additional 524,488 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Laboratory Corp. of America Holdings by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 8,702,664 shares of the company’s stock valued at $1,075,997,000 after buying an additional 308,110 shares during the last quarter. Boston Partners raised its position in shares of Laboratory Corp. of America Holdings by 7.8% in the fourth quarter. Boston Partners now owns 1,882,782 shares of the company’s stock valued at $232,787,000 after buying an additional 136,134 shares during the last quarter. Seminole Management Co. Inc. bought a new position in shares of Laboratory Corp. of America Holdings during the fourth quarter valued at $14,998,000. Finally, Winton Capital Group Ltd raised its position in shares of Laboratory Corp. of America Holdings by 41.2% in the fourth quarter. Winton Capital Group Ltd now owns 286,399 shares of the company’s stock valued at $35,410,000 after buying an additional 83,562 shares during the last quarter.

Laboratory Corporation of America Holdings is an independent clinical laboratory company in the United States. Through a national network of laboratories, the Company offers a range of clinical laboratory tests that are used by the medical profession in core testing, patient diagnosis, and in the monitoring and treatment of disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.